Background {#Sec1}
==========

With a mortality rate close to the incidence rate (331,000 deaths worldwide for 338,000 new cases in 2012 \[[@CR1]\]), pancreatic carcinoma is one of the most lethal human cancers. Advances in systemic chemotherapy and radiotherapy provided limited improvement in survival, and the 5-year overall survival (OS) remains close to 5%. Only 50% of newly diagnosed patients have a non-metastatic disease with either a resectable or borderline resectable tumor (20%) or an unresectable locally-advanced tumor (30%) \[[@CR2]\]. In patients with a resectable tumor, complete surgical removal followed by adjuvant chemotherapy is the only curative treatment. However, most of the patients display distant relapse; the median OS remains 23 months on average, and the 5-year survival is 20%. The mortality of surgery has decreased during the last 30 years, but its morbidity remains at approximately 50% \[[@CR3]\].

The high rates of patients with stage IV and experiencing distant relapses after surgery in non-metastatic stages along with preclinical data suggest that metastatic spread may precede local tumor formation \[[@CR4]\]. This has led to the emerging consensus that pancreatic cancer is a systemic disease already at diagnosis. More effective systemic therapies should confer an increased likelihood of cure after resection. Neoadjuvant chemotherapy, standardly used for borderline resectable and unresectable locally advanced diseases \[[@CR2]\], is being tested in resectable tumors with several objectives \[[@CR5]\], including early treatment of occult micrometastases, avoidance of unnecessary and morbid resection for rapidly metastasizing tumors, improvement of the likelihood of margin-negative resection, and better chemotherapy delivery than in adjuvant settings when surgical complications may delay or worsen chemotherapy tolerability. Other advantages include the ability to assess tumor response and to search for biological predictors for pathological response, which is associated with survival \[[@CR6], [@CR7]\]. Neoadjuvant chemotherapy provided interesting results in resectable pancreatic cancer in a few institutional prospective phase II studies \[[@CR8]--[@CR10]\], and randomized phase II/III studies are ongoing \[[@CR2]\]. However, this approach faces potential hurdles such as a possible missed opportunity for curative surgery and the absence of surgical staging. In this context, improving our ability to select patients for either immediate surgery or neoadjuvant chemotherapy is crucial, and represents an area of high need and intense research \[[@CR2]\].

The current prognostic factors are clinicopathological, notably based on the American Joint Committee on Cancer (AJCC) tumor, node and metastasis staging, and the criteria used for immediate surgery are technical (mainly based on the vascular involvement assessment), clinical (e.g., based on performance status), and biological (e.g., based on CA19-9 value). However, the criteria's ability to consistently predict a patient's outcome is limited, with substantial heterogeneity within the so-defined prognostic classes \[[@CR11]\]. Actually, no prognostic or predictive biomarker has yet been established for pancreatic cancer. High-throughput molecular analyses revealed the extensive heterogeneity of cancers, and notably pancreatic cancer. Key molecular alterations have been identified, such as *KRAS*, *TP53*, *SMAD4*, *CDKN2A*, and *ARID1A* mutations and *GATA6* amplification \[[@CR12], [@CR13]\], but they remain without clinical application to date. Several studies of gene expression profiling have also been reported \[[@CR14]\], mainly focused on the comparison of cancer versus normal pancreatic tissues. A few prognostic gene expression signatures have been developed \[[@CR15]--[@CR24]\], in general from small sample series and without validation in independent sets, or with validation in limited tumor sets. Biologically relevant molecular subtypes have been identified \[[@CR16], [@CR25], [@CR26]\], and associated with OS \[[@CR27]\]. However, identifying molecular predictors to aid in patient care remains necessary.

Here, we collected data of 695 pancreatic carcinoma samples from gene expression datasets, and searched for a gene expression signature predictive for post-operative OS.

Methods {#Sec2}
=======

Gene expression datasets {#Sec3}
------------------------

We retrospectively collected clinicopathological and gene expression data of clinical pancreatic carcinoma samples from nine publicly available datasets \[[@CR15], [@CR16], [@CR20], [@CR21], [@CR23], [@CR25], [@CR28]--[@CR30]\] from the National Center for Biotechnology Information/Genbank Gene Expression Omnibus, ArrayExpress, European Genome-phenome Archive, and The Cancer Genome Atlas (TCGA) databases (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Samples had been profiled using whole-genome DNA microarrays (Affymetrix or Agilent) and RNA-Seq (Illumina). The complete dataset contained 695 samples, including 601 operated primary cancer samples with available survival data. The study was approved by our institutional board.

Gene expression data analysis {#Sec4}
-----------------------------

Data analysis required pre-analytic processing. First, we normalized each DNA microarray-based dataset separately, by using quantile normalization for the available processed Agilent data, and Robust Multichip Average \[[@CR31]\] with the non-parametric quantile algorithm for the raw Affymetrix data. Normalization was performed in R using Bioconductor and associated packages. Then, we mapped hybridization probes across the different technological platforms. We used SOURCE \[[@CR32]\] and NCBI EntrezGene \[[@CR33]\] to retrieve and update the Agilent annotations, and NetAffx Annotation files \[[@CR34]\] for the Affymetrix annotations. The probes were then mapped according to their EntrezGeneID. When multiple probes represented the same GeneID, we retained the one with the highest variance in a particular dataset. For the TCGA, Bailey's and Kirby's data, we used the available normalized RNA-Seq data that we log~2~-transformed.

We defined the molecular subtypes of all pancreatic cancer samples in each dataset separately as defined in the original publications, i.e., the three Collisson's subtypes \[[@CR16]\] were classical, quasi-mesenchymal, and exocrine-like, the two Moffitt's epithelial subtypes \[[@CR26]\] were basal-like and classical, and the four Bailey's subtypes \[[@CR25]\] were squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX). To identify a prognostic expression signature, we applied a supervised analysis using learning and validation sets. The learning set was a subset (n = 39) of the Bailey's and TCGA RNA-Seq datasets that included samples from patients with survival of at least 36 months after surgery (long-term survivors (LTS); n = 17) and from patients dead of disease between 2 and 6 months after surgery (short-term survivors (STS); n = 22). The 562 other samples with available survival data from the other datasets were gathered and used as an independent validation set. Samples of the learning set were pooled before supervised analysis by using COMBAT (empirical Bayes), included in the inSilicoMerging R/Bioconductor package, as a batch effects removal method. The final merged set included 15,291 genes in log2-transformed data. The accuracy of normalization was controlled by principal component analysis (Additional file [2](#MOESM2){ref-type="media"}: Figure S1). The supervised analysis compared the expression profiles of 15,291 genes between the 22 STS samples and the 17 LTS samples using a moderated *t*-test with empirical Bayes statistic included in the Limma R packages. False discovery rate was applied to correct for the multiple testing hypothesis and significant genes were defined by the following thresholds: *P* \< 5%, false discovery rate \< 25%, and fold change superior to \|2x\|. Ontology analysis of the resulting 1400-gene list was based on the gene ontology (GO) biological processes of the Database for Annotation, Visualization and Integrated Discovery (DAVID) \[[@CR35]\]. We then developed a prognostic classifier while minimizing the number of retained genes. Starting from the resulting 1400-gene list, we used logistic regression analysis with Least Absolute Shrinkage and Selection Operator \[[@CR36]\] (LASSO), which is a selection method that handles high-dimensional regression variables with no prior feature selection step by shrinking all regression coefficients toward zero, and thus forcing many regression variables to be exactly zero. The penalty regularization parameter λ was chosen via the cross-validation routine *cv.glmnet* before running the main algorithm implemented in the R package *glmnet* version 1.9-8, with an n-fold equal to 10. The λ value was finalized by using the lambda.min, which is the value of lambda giving minimum mean cross-validated error (lambda.min was 0.0153). The resulting classifier allowed the definition of two classes of samples, namely the predicted STS-like class and the predicted LTS-like class. Its robustness was assessed in the independent validation set (n = 562) by classifying each sample in each dataset separately as STS-like or LTS-like. Since a few studies have indicated that many gene signatures were random noise signatures \[[@CR37], [@CR38]\], we evaluated whether our prognostic 25-gene signature was not inferior to random signatures. A resampling scheme was used to generate 100,000 random 25-gene signatures within the 1400 genes differentially expressed identified by supervised analysis in the learning set. Each random signature was then applied to the validation set to determine its significance level in prognostic terms for OS. We then measured the proportion of random signatures with a *P* value inferior to the *P* value from our 25-gene signature.

Statistical analysis {#Sec5}
--------------------

Associations between tumor groups and clinicopathological features were analyzed using the *t*-test or the Fisher's exact test when appropriate. Overall survival (OS) was calculated from the date of diagnosis to the date of death from pancreatic cancer. Follow-up was measured from the date of diagnosis to the date of last news for living patients. Survivals were calculated using the Kaplan--Meier method and were compared with the log-rank test. Uni- and multivariate survival analyses were performed using Cox regression analysis (Wald test). Variables tested in univariate analyses included patient age at time of diagnosis (\>60 vs. ≤ 60 years), sex (male vs. female), AJCC clinical stage (2, 3, and 4 vs. 1), pathological features including pathological type (others vs. ductal), tumor size (pT2, T3, and pT4 vs. T1), lymph node status (positive vs. negative), grade (2, 3, and 4 vs. 1), our 25-gene classification (STS-like vs. LTS-like), and the different molecular subtype classifications. Variables with a *P* value lower than 0.05 were tested in multivariate analysis. All statistical tests were two-sided at the 5% level of significance. Statistical analysis was performed using the survival package (version 2.30) in the R software (version 2.15.2) \[[@CR39]\]. We followed the reporting REcommendations for tumor MARKer prognostic studies (REMARK criteria) \[[@CR40]\]. A Sweave report describing the analysis of gene expression data and the associated statistical analysis is available as Additional file [3](#MOESM3){ref-type="media"} (Supplementary Text).

Results {#Sec6}
=======

Patient population {#Sec7}
------------------

We collected nine retrospective/prospective public whole-genome mRNA expression datasets of 695 pancreatic samples, and focused our analysis on the 601 cancer samples from patients operated from the outset and with available survival. As shown in Table [1](#Tab1){ref-type="table"}, the majority of patients were aged 60 years or older, and 54% were male. Most cases (96%) were AJCC stage 1 or 2, ductal type (98%), and grade 2 (55%). All but one case had been treated by front-line surgery, and the majority of tumors were pT2 (16%) or pT3 (77%), and pN-positive (69%). All Bailey's, Moffitt's, and Collison's molecular subtypes were represented. A total of 354 patients died. The median OS was 20 months (range, 1--156), and the 2-year OS was 40% (95% CI 36--45).Table 1Patient and tumor clinicopathological characteristics of 601 samplesCharacteristicsAll (*n* = 601)Age at diagnosis, years  ≤ 60118 (32%)  \> 60246 (68%)Sex Female170 (46%) Male197 (54%)AJCC Stage 162 (12%) 2431 (84%) 310 (2%) 412 (2%)Pathological type Ductal537 (98%) Other^a^11 (2%)Pathological grade 133 (12%) 2154 (55%) 391 (32%) 42 (1%)Pathological tumor size (pT) pT118 (5%) pT262 (16%) pT3302 (77%) pT411 (3%)Pathological lymph node status (pN) Negative141 (31%) Positive310 (69%)Collisson subtypes Classical234 (39%) Exocrine-like211 (35%) Quasi-mesenchymal156 (26%)Moffitt subtypes, 'type' Basal-like232 (39%) Classical369 (61%)Bailey subtypes ADEX140 (23%) Immunogenic104 (17%) Pancreatic progenitor142 (24%) Squamous215 (36%)Deceased354 (59%)2-year OS (95% CI)40% (36--45)Median OS, months (range)20 (1--156.4)^a^Other: 8 neuroendocrine tumors, 2 acinar cell carcinomas, 1 intraductal tubulopapillary neoplasm*ADEX* aberrantly differentiated endocrine exocrine, *AJCC* American Joint Committee on Cancer, *CI* confidence interval, *OS* overall survival

Identification of a prognostic expression signature {#Sec8}
---------------------------------------------------

We searched for a gene signature associated with OS. Supervised analysis was performed in a learning set of 39 samples selected to represent the two opposite groups of patients, including 17 LTS and 22 STS. Analysis identified 1400 genes differentially expressed between the two groups (Additional file [4](#MOESM4){ref-type="media"}: Table S2). All associated GO biological processes are shown in Additional file [5](#MOESM5){ref-type="media"}: Table S3, and the top 40 processes are shown in Table [2](#Tab2){ref-type="table"}. The robustness of those genes was tested by testing their ability to classify the LTS and STS samples from the other independent datasets. Out of the 67 samples classified, 49 (76%) were accurately classified, suggesting strong robustness (*P* = 7.68 × 10^--5^, Fisher's exact test).Table 2Top 40 gene ontology (GO) biological processes associated with the 1400 genes differentially expressed between the short-term survivor (STS) and long-term survivor (LTS) samples of the learning setGO:BP TermsIDGO:BP Terms*NP* valueStatus STS vs. LTSGO:0030198Extracellular matrix organization709.15 × 10^--26^UpGO:0007155Cell adhesion752.46 × 10^--22^UpGO:0022617Extracellular matrix disassembly352.70 × 10^--18^UpGO:0008544Epidermis development251.04 × 10^--17^UpGO:0030574Collagen catabolic process262.78 × 10^--17^UpGO:0006955Immune response501.44 × 10^--16^UpGO:0006954Inflammatory response522.34 × 10^--16^UpGO:0030199Collagen fibril organization196.76 × 10^--16^UpGO:0018149Peptide cross-linking101.23 × 10^--10^UpGO:0006935Chemotaxis222.34 × 10^--10^UpGO:0010951Negative regulation of endopeptidase activity236.65 × 10^--10^UpGO:0030216Keratinocyte differentiation143.24 × 10^--9^UpGO:0010466Negative regulation of peptidase activity81.47 × 10^--8^UpGO:0001501Skeletal system development222.51 × 10^--8^UpGO:0007160Cell-matrix adhesion191.30 × 10^--7^UpGO:0000278Mitotic cell cycle501.71 × 10^--7^UpGO:0008283Cell proliferation421.86 × 10^--7^UpGO:0031124Mrna 3-end processing6002.19 × 10^--7^UpGO:0008284Positive regulation of cell proliferation453.26 × 10^--7^UpGO:0001525Angiogenesis323.31 × 10^--7^UpGO:0019228Neuronal action potential61.26 × 10^--6^DownGO:0007409Axonogenesis121.13 × 10^--6^DownGO:0007628Adult walking behavior71.09 × 10^--6^DownGO:0007212Dopamine receptor signaling pathway57.83 × 10^--7^DownGO:0006906Vesicle fusion104.63 × 10^--7^DownGO:0030073Insulin secretion95.27 × 10^--8^DownGO:0007274Neuromuscular synaptic transmission65.20 × 10^--8^DownGO:0007399Nervous system development271.44 × 10^--8^DownGO:0014047Glutamate secretion95.89 × 10^--9^DownGO:0007626Locomotory behavior154.46 × 10^--9^DownGO:0086010Membrane depolarization during action potential81.71 × 10^--9^DownGO:0031018Endocrine pancreas development121.16 × 10^--9^DownGO:0017158Regulation of calcium ion-dependent exocytosis109.94 × 10^--10^DownGO:0006112Energy reserve metabolic process204.05 × 10^--11^DownGO:0017157Regulation of exocytosis131.60 × 10^--11^DownGO:0006813Potassium ion transport153.94 × 10^--12^DownGO:0071805Potassium ion transmembrane transport171.97 × 10^--13^DownGO:0016079Synaptic vesicle exocytosis174.00 × 10^--15^DownGO:0007269Neurotransmitter secretion197.04 × 10^--16^DownGO:0007268Synaptic transmission662.33 × 10^--37^Down

To render this signature more easily applicable in clinics, we built a multigene classifier from the 1400-gene list. Logistic regression analysis retained 25 genes (Table [3](#Tab3){ref-type="table"}), including 12 and 13 genes respectively upregulated and downregulated in the STS samples. As expected, the classifier based on these 25 genes sorted with 100% accuracy those 39 patients into two classes, with STS-like including all STS patients and LTS-like including all LTS patients.Table 3List of 25 genes included in our prognostic classifierSymbolDescriptionCytobandExpression statusGPR87G protein-coupled receptor 873q24Up STS vs. LTSKRT13keratin 13, type I17q21.2Up STS vs. LTSRAC2ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)22q13.1Up STS vs. LTSC16orf74chromosome 16 open reading frame 7416q24.1Up STS vs. LTSNAMPTnicotinamide phosphoribosyltransferase7q22.3Up STS vs. LTSDHRS9dehydrogenase/reductase (SDR family) member 92q31.1Up STS vs. LTSHIST2H2BFhistone cluster 2, H2bf1q21.2Up STS vs. LTSTREM2triggering receptor expressed on myeloid cells 26p21.1Up STS vs. LTSZDHHC20zinc finger, DHHC-type containing 2013q12.11Up STS vs. LTSCD180CD180 molecule5q12Up STS vs. LTSADGRG6adhesion G protein-coupled receptor G66q24.1Up STS vs. LTSAPBB1IPamyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein10p12.1Up STS vs. LTSEGR3early growth response 38p23-p21Down STS vs. LTSMACROD2MACRO domain containing 220p12.1Down STS vs. LTSEPHA7EPH receptor A76q16.1Down STS vs. LTSRASGEF1ARasGEF domain family, member 1A10q11.21Down STS vs. LTSSYNMsynemin, intermediate filament protein15q26.3Down STS vs. LTSS100A1S100 calcium binding protein A11q21Down STS vs. LTSWNK2WNK lysine deficient protein kinase 29q22.3Down STS vs. LTSRAMP2receptor (G protein-coupled) activity modifying protein 217q12-q21.1Down STS vs. LTSSOCS2suppressor of cytokine signaling 212qDown STS vs. LTSCOL28A1collagen, type XXVIII, alpha 17p21.3Down STS vs. LTSB4GALT6UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 618q11Down STS vs. LTSPLCB4phospholipase C, beta 420p12Down STS vs. LTSMTURNmaturin, neural progenitor differentiation regulator homolog (Xenopus)7p14.3Down STS vs. LTS

We assessed the gene overlap between our 25-gene signature and the three molecular subtype classifiers \[[@CR16], [@CR25], [@CR26]\] and five other signatures recently published that displayed robust and independent prognostic value \[[@CR15], [@CR17], [@CR20], [@CR22], [@CR30]\]. As shown in Additional file [6](#MOESM6){ref-type="media"}: Figure S2, there was no overlap with the five signatures, and the overlap with the molecular subtype classifiers was very low (0 gene with Collisson, 1 with Moffitt stroma, 2 with Moffitt tumor, and 3 with Bailey).

Validation of the 25-gene classifier and clinicopathological associations {#Sec9}
-------------------------------------------------------------------------

We tested the 25-gene prognostic classifier in the independent validation set of 562 patients whose clinicopathological characteristics were close to those of the learning set (Additional file [7](#MOESM7){ref-type="media"}: Table S4) and with a 2-year OS of 39% (95% CI 35--44; Fig. [1a](#Fig1){ref-type="fig"}). The classifier sorted the 562 patients into two classes, STS-like (*n* = 216; 38%) and LTS-like (*n* = 346; 62%), with a 2-year OS of 25% (95% CI 18--33) and 48% (95% CI 42--54), respectively (*P* = 4.33 × 10^--9^, log-rank test; Fig. [1b](#Fig1){ref-type="fig"}), thus confirming its prognostic value. The respective median OS were 15 months (range, 1--104) and 23 months (range, 1--156). Interestingly, in each of the nine datasets separately, the 2-year OS was shorter in the STS-like class than in the LTS-like class, and the difference was or tended to be significant (Additional file [8](#MOESM8){ref-type="media"}: Figure S3). To assess the likelihood of our 25-gene signature as a non-random signature, we generated by a resampling scheme 100,000 random gene signatures from the list of 1400 genes differentially expressed and tested their prognostic value in the validation set. None of the random signatures was more significant than the data-derived 25-gene signature, suggesting that the latter represented an optimal prognostic combination.Fig. 1Overall survival (OS) in the validation set according to our prognostic 25-gene classifier. Kaplan--Meier OS curves in all patients (**a**) and in all patients according to our prognostic classifier (STS-like and LTS-like classes) (**b**). The *P* values of the log-rank test are indicated

We searched for associations between the 25-gene signature-based classification and the clinicopathological variables of samples. As shown in Table [4](#Tab4){ref-type="table"}, no association was found with patient age and sex, AJCC stage, pathological type, tumor size, and lymph node status. By contrast, there were more grade 3 tumors (*P* = 1.50 × 10^--3^) in the STS-like class, and more aggressive molecular subtypes (Baileys' squamous, Collison' quasi-mesenchymal, and Moffitt's basal-like; *P* \< 0.05).Table 4Associations of our prognostic classification with clinicopathological features (validation set)Characteristics*n*LTS-like (*n* = 346)STS-like (*n* = 216)*P* valueAge at diagnosis0.219  ≤ 6010864 (31%)44 (38%)  \> 60217145 (69%)72 (62%)Sex0.419 Female157105 (50%)52 (44%) Male171106 (50%)65 (56%)AJCC stage0.759 15435 (12%)19 (11%) 2403255 (84%)148 (85%) 3105 (2%)5 (3%) 4118 (3%)3 (2%)Pathological type0.087 Ductal504308 (98%)196 (100%) Other66 (2%)0 (0%)Pathological grade1.50 × 10^--3\*^ 12724 (16%)3 (3%) 213890 (59%)48 (54%) 37538 (25%)37 (42%) 421 (1%)1 (1%)Pathological tumor size (pT)0.879 pT1159 (4%)6 (5%) pT25736 (16%)21 (16%) pT3281181 (78%)100 (76%) pT4116 (3%)5 (4%)Pathological lymph node status (pN)0.824 Negative12379 (30%)44 (29%) Positive291183 (70%)108 (71%)Collisson subtypes1.00 × 10^--6\*^ Classical223130 (38%)93 (43%) Exocrine-like194147 (42%)47 (22%) Quasi-mesenchymal14569 (20%)76 (35%)Moffitt subtypes, 'type'7.80 × 10^--15\*^ Basal-like21488 (25%)126 (58%) Classical348258 (75%)90 (42%)Bailey subtypes1.00 × 10^--6\*^ ADEX128114 (33%)14 (6%) Immunogenic10169 (20%)32 (15%) Pancreatic progenitor13390 (26%)43 (20%) Squamous20073 (21%)127 (59%)2-year OS (95% CI)56248% (42--54)25% (0.18--0.33)4.33 × 10^--9\*^Median OS, months (range)56222.8 (1--156.4)15.0 (1--103.92)*ADEX* aberrantly differentiated endocrine exocrine, *CI* confidence interval, *LTS* long-term survivors, *STS* short-term survivors, *OS* overall survival\*Statistically significant

Uni- and multivariate prognostic analyses {#Sec10}
-----------------------------------------

We compared the prognostic value of our 25-gene classifier with that of other clinicopathological variables in the validation set. In univariate analysis (Table [5](#Tab5){ref-type="table"}), three variables were associated with OS (Wald test), namely the AJCC clinical stage (*P* = 4.71 × 10^--3^), the pathological pN status (*P* = 1.24 × 10^--4^), and our 25-gene classifier (*P* = 7.47 × 10^--9^). The hazard ratio (HR) for death was 1.93 (95% CI 1.55--2.42) in the STS-like vs. LTS-like classes. In multivariate analysis, only our classifier (*P* = 6.33 × 10^--7^) and the pN status (*P* = 2.95 × 10^--2^) remained significant, suggesting an independent prognostic value. The stratification of patients according to both the classifier and the AJCC stage identified classes with different 2-year OS (Additional file [9](#MOESM9){ref-type="media"}: Figure S4). For example, in patients with stage 1 tumor, the 2-year OS was 42% in the STS-like class (42%) and 73% in the LTS-like class (*P* = 6.74 × 10^--3^, log-rank test). Stage 2 patients were similarly subdivided into STS- and LTS-like with a 21% and 46% 2-year OS (*P* = 4.37 × 10^--7^, log-rank test), respectively.Table 5Uni- and multivariate Cox regression analyses for overall survival (validation set)CharacteristicsUnivariateMultivariateMultivariate*N*HR (95% CI)*P* value*N*HR (95% CI)*P* value*N*HR (95% CI)*P* valueAge at diagnosis\>60 vs. ≤ 603251.22 (0.88--1.70)0.234SexMale vs. female3281.08 (0.80--1.45)0.633AJCC Stage2 vs. 14782.01 (1.32--3.07)4.71 × 10^--3\*^4081.57 (0.88--2.82)0.1283 vs. 13.11 (1.33--7.23)4082.21 (0.82--5.97)0.1194 vs. 12.85 (1.16--7.05)4081.44 (0.19--10.97)0.723Pathological typeOther vs. ductal5100.36 (0.09--1.45)0.151Pathological grade2 vs. 12421.52 (0.65-- 3.55)0.1853 vs. 12.15 (0.91-- 5.11)4 vs. 12.66 (0.53--13.3)Pathological tumor size (pT)2 vs. 13641.49 (0.62--3.59)0.1313 vs. 11.95 (0.86--4.42)4 vs. 12.93 (1.01--8.48)Pathological lymph node status (pN)1 vs. 04141.83 (1.34--2.48)1.24 × 10^--4\*^4081.50 (1.04--2.16)2.95 × 10^--2\*^Collisson subtypesExocrine-like vs. classical5621.00 (0.77--1.29)2.32 × 10^--3\*^5620.94 (0.66--1.34)0.732Quasi-mesenchymal vs. classical1.52 (1.17--1.99)5621.15 (0.83--1.59)0.395Moffitt subtypes, 'type'Classical vs. basal-like5620.64 (0.51--0.80)6.29 × 10^--5\*^5621.00 (0.72--1.38)0.994Bailey subtypesImmunogenic vs. ADEX5620.81 (0.57--1.17)8.98 × 10^--6\*^5620.68 (0.43--1.06)0.090Pancreatic progenitor vs. ADEX0.97 (0.70--1.35)5620.79 (0.51--1.23)0.302Squamous vs. ADEX1.64 (1.22--2.19)5621.09 (0.68--1.74)0.73125-gene classifierSTS-like vs. LTS-like5621.93 (1.55--2.42)7.47 × 10^--9\*^4082.04 (1.54--2.70)6.33 × 10^--7\*^5621.77 (1.38--2.26)6.33 × 10^--6\*^*ADEX* aberrantly differentiated endocrine exocrine, *CI* confidence interval, *HR* hazard ration, *LTS* long-term survivors, *STS* short-term survivors\*Statistically significant

Given the association between the molecular subtypes and the 25-gene classifier, we compared their respective prognostic performance. In univariate analysis, the three molecular subtype classifiers confirmed their prognostic value in this large sample set (Additional file [10](#MOESM10){ref-type="media"}: Figure S5). However, in multivariate analysis including the four multigene classifiers, only our 25-gene classifier remained significant (*P* = 6.33 × 10^--6^, Wald test, Table [5](#Tab5){ref-type="table"}) with a HR of 1.77 (95% CI 1.38--2.26). As shown in Fig. [2](#Fig2){ref-type="fig"}, it affected the clinical outcome of all molecular subtypes of all three classifications, except the Bailey's progenitor subtype.Fig. 2Overall survival (OS) in the validation set according to our prognostic 25-gene classifier and the molecular subtypes. Kaplan--Meier OS curves according to our prognostic classifier (STS-like and LTS-like classes) and the molecular subtypes defined by Bailey (**a** pancreatic progenitor; **b** immunogenic; **c** ADEX; **d** squamous), Collison (**e** exocrine-like; **f** classical; **g** quasi-mesenchymal), and Moffitt (**h** classical; **i** basal-like). The *P* values (log-rank test) for the comparison between the two classes within each molecular subtype are indicated

Discussion {#Sec11}
==========

Pancreatic carcinoma is a heterogeneous disease with high metastatic propensity and poor prognosis. In patients with resectable disease, the development of effective systemic therapies is crucial. During the last decades, several retrospective studies \[[@CR41]\] and a few prospective phase II studies \[[@CR8]--[@CR10]\] have suggested the potential benefit of neoadjuvant chemotherapy, and large randomized phase II/III trials are ongoing. In this context, a major challenge is to improve the imperfect current prognostic factors to aid in therapeutic decision-making, notably regarding the decision for immediate surgery followed by chemotherapy or neoadjuvant chemotherapy followed by surgery. Here, we have analyzed whole-genome expression profiles of 601 pancreatic carcinoma samples from operated patients, and identified a robust 25-gene classifier associated with post-operative OS independently of classical prognostic factors and molecular subtypes. To our knowledge, this study is by far the largest prognostic study of gene expression profiles in pancreatic carcinoma.

Gene expression profiling remains today the most promising and successful high-throughput molecular approach to identify new prognostic tools in early-stage cancers. Multigene signatures are already marketed, such as Oncotype™ in breast cancer or Coloprint™ in colon cancer, yet no similar signature is available in pancreatic carcinoma. The paucity of tumor specimens available for analysis explains the relatively small number of samples profiled in previous prognostic studies, with 102 samples in the largest one \[[@CR20]\] to use supervised analysis, and 328 in the Australian ICGC study \[[@CR25]\], which identified prognostic molecular subtypes by unsupervised analysis. We overcame the problem by pooling nine public datasets, representing a total of 601 operated primary cancers with available follow-up, and allowing the use of a learning set and a validation set in the supervised analysis. Our series displayed classical clinicopathological characteristics and poor prognosis with a 40% 2-year OS. The learning set, which included only 39 samples, was remarkably small compared with the validation set; this might have reduced our ability to capture the best genes for the classifier. However, it was carefully designed to contain two groups with distinct aggressiveness, namely a LTS group after surgery and a STS group, and to contain samples profiled using the same technology (RNA-Seq). Such design likely explains the large number of genes (1400) differentially expressed between the two patient groups despite the correction for the multiple testing hypothesis, and the robustness of our final signature in the validation set. A similar design had been used previously \[[@CR20]\] by comparing primary tumors from metastatic versus non-metastatic patients. The size of our series allowed testing of the classifier in a large independent validation set of 562 samples with multivariate analysis and increased statistical power. For comparison, the other prognostic expression signatures published to date in pancreatic cancer \[[@CR15]--[@CR24]\] were defined in learning sets including 6--70 clinical samples, then tested in validation sets including 67--246 samples, with inconstant multivariate analysis.

We first identified 1400 genes differentially expressed between the STS and LTS samples. From this gene list, a 25-gene classifier was developed, identifying two classes, namely STS-like and LTS-like. The prognostic value was verified in the independent validation set, in which the two classes, STS-like (38% of samples) and LTS-like (62%), showed a different 2-year OS (25% in the STS-like and 48% in the LTS-like). Interestingly, and by contrast to the other published studies in the field, this prognostic value existed in each of the nine datasets considered separately. As expected, the other variables significant in univariate analysis included the AJCC stage and the pathological lymph node status. The pathological type (other vs. ductal) was not significant (HR 0.36 with *P* = 0.151) because of the small percentage (1%) of "other" types. Interestingly, all six "other" type samples were classified in the LTS-like class, in agreement with the better prognosis of neuroendocrine tumors. Importantly, the OS analysis was not modified when limited to the 504 ductal samples with a 27% 2-year OS in the STS-like and 48% in the LTS-like. Our 25-gene classifier displayed an independent prognostic value. Interestingly, it outperformed the molecular subtypes in multivariate analysis and identified patients with shorter and longer survival in all subtypes but one, highlighting substantial heterogeneity in each of them. None of the 100,000 25-gene signatures randomly generated by a resampling scheme was more significant than the data-derived 25-gene signature, suggesting that this latter represented a non-random optimal prognostic combination.

Ontology analysis of the 25 genes revealed interesting pathways, such as pathways related to the metastatic process (extracellular matrix organization and disassembly, cell and cell-matrix adhesion), local inflammation (immune and inflammatory responses, chemotaxis), and cell proliferation (mitotic cell cycle, positive regulation of proliferation) associated with the "poor-prognosis genes". Pathways associated with the "good-prognosis genes" included those related to pancreas metabolism (endocrine pancreas development, energy reserve metabolic process, insulin secretion) or synaptic connections (synaptic transmission and vesicle exocytosis, membrane depolarization during action potential). Whether the 25 classifier genes are causative of the phenotype in a biological sense or reflect another associated phenomenon remain to be explored. However, it was interesting to find some genes already reported as associated with cancer biology and/or to the clinical outcome of cancer patients. Among the genes upregulated in STS, *GPR87*, *RAC2*, *NAMPT*, *C16orf74*, *TREM2*, and *CD180* are involved in NF-~K~B-mediated cell signaling, and *KRT13*, *RAC2*, *C16orf74*, *ADGRG6*, and *APBB1IP* in epithelial--mesenchymal transition. These two pathways are frequently affected in pancreatic ductal adenocarcinoma (PDAC) \[[@CR42], [@CR43]\]. Activation of the NF-~K~B signaling pathway plays an important role in the development and progression of disease and impacts the epithelial--mesenchymal transition, chemoresistance, migration, and invasion of pancreatic cancer cells \[[@CR42], [@CR44]--[@CR46]\]. The NF-~K~B activation pathway picked by our signature might not necessarily be related to tumor cells themselves. Stromal cells can modulate their activation status through NF-~K~B, based on the signals collected from their environment. TREM2 and CD180 are negative regulators of the Toll-like receptor pathway \[[@CR47]\], a family of receptors that recognize damage-associated molecule patterns, whose increased serum levels have been associated with cancer \[[@CR48]\]. Inhibition of Toll-like receptors results in impaired immediate host defensive responses and anti-tumor response mounting. TREM2 and CD180 are also part of the conventional markers used to describe "alternatively" activated M2 macrophages. M2 macrophages promote angiogenesis, tissue remodeling and repair, thus facilitating tumor progression and invasion, and their presence is correlated with poor prognosis in several cancers, including PDAC \[[@CR49], [@CR50]\]. Identifying molecules that modulate some specific "activation nodes" of the wide NF-~K~B signaling pathway could be interesting for pancreatic cancer therapy. Two other genes related to NF-~K~B activation are *GPR87* and *NAMPT*, and represent potential therapeutic targets. *GPR87* is overexpressed in various cancers, including pancreatic cancer cells and tissues, and its overexpression correlates with shorter OS \[[@CR51]\]. GPR87 enhances pancreatic cancer aggressiveness by activating the NF-~K~B signaling pathway, and plays a role in tumor cell survival \[[@CR52], [@CR53]\] and the regulation of TP53 \[[@CR54]\]. Antagonists of GPR87 are in development \[[@CR53]\]. *NAMPT* is one of the two enzymes regulating the NAD+ salvage pathway, a vital pathway allowing pancreatic cancer cells to maintain their metabolism, notably in hypoxic conditions \[[@CR55]\]. *NAMPT* is also involved in tumor angiogenesis \[[@CR56], [@CR57]\]. Thus, targeting *NAMPT* may not only disturb the salvage pathway on which pancreatic tumor cells heavily rely, but may also "normalize" blood vessels in the tumor, a phenomenon that will improve the delivery and efficacy of anticancer treatments and relieve immunosuppression \[[@CR58], [@CR59]\]. Several NAMPT inhibitors are currently in development in oncology \[[@CR60]\]. For example, FK866, a non-competitive highly specific inhibitor of NAMPT, shows potent anti-tumor activity both in vitro and in vivo \[[@CR61]\] on pancreatic cancer samples overexpressing *NAMPT* mRNA. Among the other genes of our signature upregulated in STS samples are *C16orf74* and *KRT13*, which are associated with poor OS in pancreatic \[[@CR62]\] and prostate \[[@CR63]\] cancers.

Thirteen genes of our signature were downregulated in STS samples. Three of them, *EGR3*, *EPHA7*, and *MACROD2*, play a role in peripheral nervous system biology, which may have a role in PDAC aggressiveness \[[@CR64]\]. We previously reported that the *MACROD2* locus at chromosome 20p12.1 may be a cancer-specific fragile site often affected in PDAC \[[@CR65]\]. Four genes (*EPHA7*, *SOCS2*, *SYNM*, *WNK2*) are tumor suppressor genes whose hypermethylation is a common mechanism of downregulation. WNK2 is a serine-threonine kinase involved in the regulation of electrolyte homeostasis, cell survival, and proliferation. Its downregulation occurs early in PDAC oncogenesis \[[@CR66]\]. SOCS2 is an important regulator of the JAK-STAT pathway \[[@CR67]\]. SYNM is a type IV intermediate filament involved in the modulation of cell adhesion and motility; in breast cancer, SYNM methylation is associated with shorter recurrence-free survival \[[@CR68]\].

Conclusions {#Sec12}
===========

We have identified a 25-gene classifier associated with post-operative OS independently of classical prognostic factors and molecular subtypes. The strength of our study lies in the size of the series, the robustness of the classifier in a large and multicentric validation set and in each dataset separately, its independent prognostic value, its non-random nature, and the biological relevance of the included genes. The small number of genes should facilitate the clinical application of the classifier by using other transcriptional tests applicable to formaldehyde-fixed paraffin-embedded samples such as qRT-PCR, RNAscope™ or Nanostring™ technologies. Limitations include the retrospective nature of our series and associated biases. Despite the very high *P* values, the HR for death was relatively low, around 2, in both uni- and multivariate analyses, and therefore of uncertain clinical value. However, we think that the testing of our signature in the current prospective trials of adjuvant and neoadjuvant chemotherapy trials is warranted, and should be tested not only as a two-tiered classifier, but also as a continuous score. Indeed, a continuous score based on the expression of 25 genes showed significant prognostic value (data not shown) in univariate analysis (HR for death of 2.84 (95% CI 2.06--3.91), *P* = 1.96 × 10^--10^) and in multivariate analysis (HR for death of 3.25 (95% CI 2.11--4.99), *P* = 7.42 × 10^--8^). If validated, our signature could help select patients with resectable disease for either immediate surgery (for the predicted LTS-like patients) or neoadjuvant chemotherapy (for the predicted STS-like patients), which ultimately should affect outcome and impact quality of life. Of course, the clinical utility of this approach will have to be prospectively demonstrated prior to any use in clinical routine. Neoadjuvant chemotherapy, currently mainly based on anatomical considerations, might also be indicated, and its benefits maximized, on the basis of the expression profile of aggressiveness, regardless of resectability. Finally, some of the classifier genes, or the pathways in which they are involved, may represent therapeutic targets. Therefore, functional studies to assess this are warranted.
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